Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Reddy’s Accuses Amarin Of ‘Illegally’ Blocking Vascepa API Supply

Indian Firm Has Sued Originator In A New Jersey Court

Executive Summary

Having sat on an approved Vascepa ANDA since August last year, Dr Reddy’s Laboratories has sued originator Amarin, claiming the firm has illegally cornered the market for the hard-to-manufacture active ingredient.

You may also be interested in...



Hikma Raises Expectations For 2021 After A Host Of Launches

On the back of a string of launches in 2021 – including the full introduction to the US market of its generic rival to Advair – Hikma has raised its full-year forecast for its generics business in anticipation of a healthy second half.

Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin

Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.

Teva Vascepa ANDA Is ‘Discontinued’ Despite Settlement Agreement

Teva was in position to introduce further generic competition to Amarin’s Vascepa following legal setbacks for the originator. However, the firm’s ANDA has since been listed as discontinued.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel